ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Radiation Oncology

Radiation Oncology

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

Older soft-tissue sarcoma patients undergoing surgery derive greater benefit from radiotherapy than younger patients, according to a surprising analysis of more than 15,000 individuals.

During the past decade, scientific evidence has emerged that shows that radiotherapy can induce: A) immunogenic cell death, a form of cancer cell death that is effectively signaling to the immune system; and B) a series of “danger” and pro-immunogenic signals that are sensed by the host’s immune system, and can be harnessed to reject the tumor.

The combination of chemotherapy and radiation therapy resulted in longer overall survival than radiation alone in certain patients with grade 2 gliomas, according to long-term results from a randomized trial.

The phase III HYPRO study failed to prove the non-inferiority of using hypofractionated radiotherapy compared with fractionated radiotherapy for late genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer.

A large cohort study showed that the risk of colorectal cancer is increased following a diagnosis of prostate cancer, suggesting colorectal cancer screening should be considered following a prostate cancer diagnosis.

Men who receive radiation therapy as treatment for their prostate cancer may have an increased risk of developing a secondary cancer, according to a meta-analysis of observational studies.

Pages

Subscribe to Radiation Oncology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.